The global single-use bioreactors market is projected to reach USD 9.1 billion by 2029 from USD 4.4 billion in 2024, at a CAGR of 15.4% during the forecast period of 2024 to 2029. Growth in the single-use bioreactors market can be attributed to factors such as growing adoption among CDMOs, CMOs, and SMEs, advantages over conventional bioreactors, reduced capital investment, reduced water and energy consumption, and growing biologics & biosimilars markets. On the other hand, issues related to extractables & leachables, regulatory hurdles and compliance issues, and impact of PFAS restrictions on product development are expected to hinder market growth.
The global single-use bioreactors market is competitive, with Sartorius AG (Germany), Danaher Corporation (US), Thermo Fisher Scientific Inc. (US) and Merck KGaA (Germany) accounting for the 70-80% of the market share globally.
Sartorius AG provides an extensive range of single-use bioreactor products for end users such as biopharmaceutical & pharmaceutical companies, CMOs, and CROs. The company’s strong focus on a broad range of customer-centric and technology-enabled solutions, significant investments in R&D, and a comprehensive product line comprising high-quality products are contributing to its growing share in the single-use bioreactors market. With a strong geographic presence and continuous expansions in developed and developing regions, the company is expected to grow at a high rate in the single-use bioreactors market during the forecast period.
Danaher Corporation provides cell culture, filtration, separation, and purification technologies for the medical, biopharmaceutical, and food & beverage industries through its subsidiary, Cytiva (a part of the Life Sciences business). The company is one of the top players in the single-use bioreactors market with its strong portfolio of single-use bioreactors solutions. Its bioprocessing single-use technologies facilitate the development and commercialization of chemically synthesized and biologically derived drugs, plasma, and vaccines.
Thermo Fisher Scientific, Inc. offers a broad spectrum of single-use bioreactor products. This wide array allows it to serve diverse market needs effectively. As a leading player with a high market share, it has significant influence over market trends and customer preferences, leveraging its established reputation to maintain leadership. Continuous investment in R&D ensures the company remains at the forefront of technological advancements, addressing emerging challenges and opportunities in bioprocessing.
Increasing adoption of SUBs among small companies and startups
Reduced automation complexity
Ease in the cultivation of marine organisms
Reduced energy and water consumption
Growing biologics market
Technological advancements in SUBs
Increasing biopharmaceutical R&D
Restraints:
Regulatory concerns related to SUBs
Issues related to leachables and extractables
Opportunities:
Patent expiry
Emerging markets
Challenges:
Need for improved single-use sensors
Standardization of single-use designs
Recent Developments:
In November 2022, Sartorius GA (Germany) planned to invest in growing its operations by establishing new R&D laboratories and digitalizing & automating equipment, among other approaches. This development was aimed at meeting the high demand from the biopharmaceutical industry.
In November 2022, Danaher Corporation (US) subsidiary, Cytiva invested around USD 8 million to expand its Fast Trak center in Shanghai, China. The Single-use Technologies (SUT) center of excellence in Asia offers new product R&D tests and validation with an aim to facilitate the industry's application of SUT throughout the region.
In August 2022, Thermo Fisher Scientific (US) opened its largest single-use technology manufacturing site in Greater Nashville with an investment of USD 105 million to meet the growing demand for the bioprocessing materials needed to produce vaccines and breakthrough therapies for cancer and other diseases.
Single-Use Bioreactors Market Advantages:
Cost Efficiency: Single-use bioreactors are cost-efficient, as they require fewer amounts of investments in terms of purchase, operation and maintenance. This, in turn, reduces the overall cost of production.
Easy to Install and Operate: Single-use bioreactors are easy to install and operate, as they require minimal training and do not require complex infrastructure. This makes them an ideal choice for small-scale production.
Increased Productivity: The use of single-use bioreactors can increase productivity, as they can be used to perform multiple processes in a single batch. This reduces the time required to complete the process.
Reduced Risk of Contamination: Single-use bioreactors reduce the risk of contamination, as they do not require cleaning between batches. This enables manufacturers to produce high-quality products with minimal risk of contamination.
Flexibility: Single-use bioreactors provide manufacturers with flexibility, as they can be used for a variety of processes and products. This reduces the cost of production, as manufacturers do not need to purchase multiple bioreactors for different processes.
Market sizes are updated for the base year 2022 and forecasted from 2023 to 2028.
The market overview chapter in this current edition of the report provides the ecosystem analysis, key conferences & events during 2023–24, regulatory analysis, and the key stakeholders and buying criteria in the single-use bioreactors market.
The current edition of the report provides updated financial information for each listed company in a graphical representation. This will help in the easy analysis of the present status of profiled companies in terms of their financial strength, profitability, key revenue-generating region/country, and business segment focus in terms of the highest revenue-generating segment.
Recent developments are helpful in understanding market trends and growth strategies adopted by players in the market. The number of product launches has increased in the last three years (January 2020 to February 2023).
Tracking product portfolios of prominent market players helps to analyze the major products in the single-use bioreactors market. The new edition of the report provides an updated product portfolio of the companies profiled in the report.
The market evaluation framework, market share analysis, and competitive leadership mapping have been updated in the competitive landscape chapter of the report. The current version of the report includes the revenue share analysis of key market players from 2020 to 2022.
This updated section is an output of a comprehensive study of the key vendors offering single-use bioreactors. The top 25 vendors were shortlisted from a list of 50+ vendors, and these were evaluated based on the market share/ranking and product footprint, rated and positioned on a 2x2 quadrant, referred to as Company Evaluation Quadrant, categorizing them as 'Stars,' 'Emerging Leaders,' 'Pervasive Players,' and 'Emerging Companies.'
A comprehensive study of the key startup vendors offering single-use bioreactors was also performed. The top 15 vendors were shortlisted from a list of 50+ vendors. These were evaluated based on the market share/ranking and product footprint, rated and positioned on a 2x2 quadrant, referred to as Competitive Leadership Quadrant, categorizing them as 'Progressive Companies,' 'Starting Blocks,' 'Responsive Companies,' and 'Dynamic Companies.'
The market size has been updated for the base year 2022 and is forecasted from 2023 to 2028.
The current edition of the report includes an assessment of the economic and financial recession and geographical conditions such as supply chain disruptions, the Russia-Ukraine war, along with the effects of inflation on the single-use bioreactors market. The impact of the recession on year-on-year growth during the forecast period (2023 to 2028) has also been considered.
